Search is Powered by Google
Cancer / Oncology News

Socioeconomic Differences Can Predict Outcomes For Most Melanoma Patients But Not For Blacks, Study Says

Main Category: Cancer / Oncology
Article Date: 23 Jan 2008 - 6:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:3 stars

3 (1 votes)

Article Opinions: 0 posts

Although socioeconomic status can strongly predict outcomes for people with melanoma, it does not explain poor overall survival among blacks with skin cancer, according to a study in the Journal of Clinical Oncology, Reuters reports.

The study looked at 34,049 patients diagnosed with melanoma between 1993 and 2003. According to the study, people with higher socioeconomic status were more likely than those with lower socioeconomic status to be diagnosed with melanoma at an early stage, have surgery to remove tumors and survive longer. Those with the highest socioeconomic status were 37% less likely to die, even after accounting for differences in age, gender, cancer stage and other factors.

African-Americans were 60% more likely than non-Hispanic whites to die from melanoma, while there were no differences in survival among Asians, Hispanics and non-Hispanic whites, the study found. Study researcher Jason Zell of the University of California-Irvine said that while melanoma is not very common among blacks, the study showed that "survival among African-American melanoma patients is poor" and cannot be explained by differences in cancer stage, treatment or socioeconomic factors (Rauscher, Reuters, 1/21).

An abstract of the study is available online.

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Shocking Pictures To Appear On Cigarette Packets In UK On 1st October
27 Sep 2008
The UK's ten million Smokers may see pictures of rotting teeth, throat cancer, and indications of male impotence (erectile dysfunction) on cigarette packets they buy at the beginning of October...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...